# US 2010/0167270 A1 · Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167270 A1
- Document ID: US20100167270A1
- Status: Published application
- Kind: A1
- Application number: 12/640,808
- Filed: 2009-12-17
- Published: 2010-07-01
- Earliest claimed: 2005-03-10
- Assignees: Medlmmune, LLC
- Inventors: Jeanne H. Schickli
- Web page: https://patentgrep.com/patent/US20100167270A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/37: involving peptidase or proteinase
- A61K 2039/525: {Virus}
- C12N 2760/18321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/18322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18343: viral genome or elements thereof as genetic vector
- C12Q 1/701: {Specific hybridization probes}
- G01N 2333/115: Paramyxoviridae, e.g. parainfluenza virus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to improved strains of mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention further relates to methods for propagating mammalian MPV in the absence of trypsin. The methods and compositions of the invention can be used for the preparation of vaccines against, e.g., MPV infections.

## Claims

### Claim 1

A method for propagating mammalian metapneumovirus, wherein the method comprises culturing the mammalian metapneumovirus in medium with a specific trypsin activity of less than 20 milliunits per milliliter of medium.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mammalian metapneumovirus is human metapneumovirus.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein no trypsin is added exogenously to the medium.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein no serum is added to the medium.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein an RQSR cleavage motif in the cleavage site of the F protein of mammalian metapneumovirus comprises at least one amino acid substitution.

### Claim 6 (depends on 5)

The method of claim 5, wherein the F protein of mammalian metapneumovirus comprises at least one additional amino acid substitution relative to SEQ ID NO:314.

### Claim 7 (depends on 5)

The method of claim 5, wherein the amino acid substitution in the RQSR cleavage motif is a serine to proline substitution resulting in a RQPR sequence.

### Claim 8 (depends on 6)

The method of claim 6, wherein the additional amino acid substitution in the F protein is at least one of the following E93K, Q100K, E92K, E93V, I95S, E96K, Q94K, Q94H, I95S, N97K or N97H.

### Claim 9 (depends on 8)

The method of claim 8, wherein the additional amino acid substitution in the F protein is E93K.

### Claim 10 (depends on 6)

The method of claim 6, wherein the additional amino acid substitution stabilizes the amino acid substitution in the RQSR motif.

### Claim 11

An isolated mammalian metapneumovirus, wherein the mammalian metapneumovirus is capable of growth in the absence of trypsin.

### Claim 12 (depends on 11)

The virus of claim 11, wherein the mammalian metapneumovirus is human metapneumovirus.

### Claim 13 (depends on 11, 12)

The virus of claim 11 or 12, wherein an RQSR cleavage motif in the cleavage site of the F protein of mammalian metapneumovirus comprises at least one amino acid substitution.

### Claim 14 (depends on 13)

The virus of claim 13, wherein the F protein of mammalian metapneumovirus comprises at least one additional amino acid substitution relative to SEQ ID NO:314.

### Claim 15 (depends on 13)

The virus of claim 13, wherein the amino acid substitution in the RQSR cleavage motif is a serine to proline substitution resulting in a RQPR sequence.

### Claim 16 (depends on 14)

The virus of claim 14, wherein the additional amino acid substitution in the F protein is at least one of the following E93K, Q100K, E92K, E93V, I95S, E96K, Q94K, Q94H, I95S, N97K or N97H.

### Claim 17 (depends on 14)

The virus of claim 14, wherein the additional amino acid substitution stabilizes the amino acid substitution in the RQSR motif.

### Claim 18 (depends on 16)

The virus of claim 16, wherein the additional amino acid substitution in the F protein is E93K.

### Claim 19

An isolated nucleic acid, wherein the isolated nucleic acid encodes an F protein of a mammalian metapneumovirus, wherein the F protein comprises the S101P amino acid substitution and at least one of the following amino acid substitutions E93K, Q100K, E92K, E93V, I95S, E96K, Q94K, Q94H, I95S, N97K or N97H.

### Claim 20 (depends on 19)

The nucleic acid of claim 19, wherein the mammalian metapneumovirus is human metapneumovirus.

### Claim 21

A method for identifying an F protein of a mammalian metapneumovirus that supports stable growth of the mammalian metapneumovirus in the absence of trypsin, the method comprising:
(a) growing the mammalian metapneumovirus in the absence of trypsin for at least two passages, wherein the mammalian metapneumovirus comprises a RQPR motif in the cleavage site of the F protein; and
(b) measuring syncytia formation;
wherein increased syncytia formation relative to syncytia formation by a mammalian metapneumovirus prior to step (a) indicates that the F protein of the mammalian metapneumovirus has acquired an additional amino acid substitution that supports stable growth of the mammalian metapneumovirus in the absence of trypsin.

### Claim 22

A method for identifying an F protein of a mammalian metapneumovirus that supports stable growth of the mammalian metapneumovirus in the absence of trypsin, the method comprising:
(a) growing the mammalian metapneumovirus in the absence of trypsin for at least two passages, wherein the mammalian metapneumovirus comprises a RQPR motif in the cleavage site of the F protein; and
(b) measuring F protein cleavage;
wherein increased F protein cleavage relative to F protein cleavage by mammalian metapneumovirus prior to step (a) indicates that the F protein of the mammalian metapneumovirus has acquired an additional amino acid substitution that supports stable growth of the mammalian metapneumovirus in the absence of trypsin.

### Claim 23

A method for identifying an F protein mutant of a mammalian metapneumovirus that enhances trypsin-independent cleavage of the F protein, wherein the F protein comprises a RQPR motif in the cleavage site, said method comprising:
(a) growing the mammalian metapneumovirus in the absence of trypsin for at least two passages; and
(b) determining the cleave efficiency of the F protein,
wherein increased cleavage efficiency of the F protein indicates that the F protein has acquired a mutation that enhances trypsin-independent cleavage of the F protein.

### Claim 24

A method for identifying a protease that catalyzes the cleavage of an F protein of mammalian metapneumovirus, wherein the F protein comprises a RQPR motif in the cleavage site, said method comprising:
(a) contacting the F protein with a test protease; and
(b) determining whether cleavage of the F protein has occurred;
wherein the occurrence of cleavage of the F protein indicates that the protease catalyzes the cleavage of the F protein.

### Claim 25 (depends on 21, 22, 23)

The method of claim 21, 22, 23, or 24, wherein the mammalian metapneumovirus is human metapneumovirus.

### Claim 26 (depends on 21, 22, 23)

The method of claim 21, 22, 23, or 24, wherein the mammalian metapneumovirus carries the S101P mutation.
